{"id":5770,"date":"2023-04-18T11:34:11","date_gmt":"2023-04-18T09:34:11","guid":{"rendered":"http:\/\/164.90.225.225\/o-nas\/"},"modified":"2024-09-16T15:35:31","modified_gmt":"2024-09-16T13:35:31","slug":"o-nas","status":"publish","type":"page","link":"https:\/\/www.quinta.cz\/cs\/o-nas\/","title":{"rendered":"O n\u00e1s"},"content":{"rendered":"

<\/div><\/div><\/span>

Quinta-Analytica
\nKdo jsme?<\/p><\/h1><\/span>

<\/div><\/div><\/div>
<\/span><\/div><\/div><\/div>

Jsme dynamick\u00fdm sv\u011btov\u00fdm poskytovatelem \u0161pi\u010dkov\u00fdch slu\u017eeb v oblasti anal\u00fdzy l\u00e9\u010div, klinick\u00fdch studi\u00ed a bioanalytick\u00e9ho testov\u00e1n\u00ed. Na\u0161\u00edm c\u00edlem a filozofi\u00ed je zajistit, aby se Va\u0161e l\u00e9\u010div\u00e9 p\u0159\u00edpravky dostaly na trh v\u010das, v nejvy\u0161\u0161\u00ed mo\u017en\u00e9 kvalit\u011b a p\u0159esn\u011b podle Va\u0161ich specifikac\u00ed.
\n– Roman Grunt, CEO<\/strong><\/em><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

VEDOUC\u00cd T\u00ddM<\/a><\/p>\n<\/div><\/div><\/div>

V\u011aDECK\u00c1 RADA<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/div><\/div><\/div><\/div>
<\/span><\/div>

Full-service CRO pro mal\u00e9 molekuly, biologika a biosimilars, v\u010detn\u011b hum\u00e1nn\u00edch i veterin\u00e1rn\u00edch IMP<\/p>\n<\/div><\/div><\/div>

<\/span><\/div>

Od BE\/BA\/PK studi\u00ed p\u0159es GLP\/GCP bioanalytiku a GMP QC a\u017e po analytick\u00fd R&D a CMC podporu<\/p>\n<\/div><\/div><\/div>

<\/span><\/div>

Z\u00e1zem\u00ed ve st\u0159edn\u00ed Evrop\u011b (Praha\/Brno\/Ostrava) s glob\u00e1ln\u00ed dod\u00e1vkou slu\u017eeb v re\u017eimu GxP<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>\n

<\/lite-youtube><\/div><\/div><\/div><\/div><\/div><\/div>\n
<\/div><\/div><\/span>

N\u00e1\u0161 t\u00fdm. Na\u0161e hodnoty.<\/h2><\/span>
<\/div><\/div><\/div>

N\u00e1\u0161 p\u0159\u00edstup vych\u00e1z\u00ed z toho, \u017ee m\u00e1me v na\u0161em t\u00fdmu jedny z nejzku\u0161en\u011bj\u0161\u00edch a nejtalentovan\u011bj\u0161\u00edch v\u011bdc\u016f, kte\u0159\u00ed tvo\u0159\u00ed skute\u010dn\u00e9 centrum excelence. V\u00fdsledkem slou\u010den\u00ed sofistikovanosti modern\u00ed farmaceutick\u00e9 praxe se zku\u0161enostmi talentovan\u00fdch odborn\u00edk\u016f nab\u00edz\u00edme nenapodobiteln\u00fd produkt:
\nquintessence<\/span>.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>
<\/div><\/div><\/span>

Roman Grunt
\n\u0158editel<\/p><\/h3><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div>

Vystudoval \u010cVUT v Praze, strojn\u00ed fakultu a London Business school, corporate finance. Od roku 1996 pracoval ve spole\u010dnosti Ernst & Young v Praze a v Curychu.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
\n

Od roku 2000 pracoval na finan\u010dn\u00edch pozic\u00edch ve spole\u010dnosti Zentiva, \u00fa\u010dastnil se akvizic na Slovensku, Rumunsku a Turecku. B\u011bhem roku 2008 se p\u0159esunul na pozici CFO Eczacibasi-Zentiva Turecko. Pozd\u011bji, b\u011bhem roku 2010, p\u0159e\u0161el do \u010cEZ Turecko jako CFO. Na podzim roku 2013 se stal Gener\u00e1ln\u00edm \u0159editelem spole\u010dnosti FARMAK, od roku 2017 zast\u00e1v\u00e1 pozici CEO ve spole\u010dnosti QUINTA-ANALYTICA.<\/p>\n<\/div><\/div><\/div><\/div><\/div>

<\/a><\/span><\/div>
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Marcela P\u00edsa\u010dkov\u00e1
\nProvozn\u00ed \u0159editelka<\/p><\/h3><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div>

Marcela P\u00edsa\u010dkov\u00e1 vystudovala chemii na Karlov\u011b Univerzit\u011b v Praze. Absolvovala kurz Kvalifikovan\u00e9 osoby ve farmaceutick\u00e9m pr\u016fmyslu a postgradu\u00e1ln\u00ed kurzy Spr\u00e1vn\u00e9 praxe v kontroln\u00ed laborato\u0159i a Farmaceutick\u00e1 analytick\u00e1 kontrola.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
Do spole\u010dnosti QUINTA-ANALYTICA nastoupila v roce 1999 jako v\u00fdzkumn\u00fd pracovn\u00edk a od t\u00e9 doby pro\u0161la mnoha rolemi v\u010detn\u011b projektov\u00e9ho koordin\u00e1tora a vedouc\u00ed ji\u0161t\u011bn\u00ed jakosti. Od roku 2017 je v pozici Provozn\u00ed \u0159editelky zodpov\u011bdn\u00e9 za farmaceutick\u00e9 a bioanalytick\u00e9 anal\u00fdzy.<\/div><\/div><\/div><\/div><\/div>
<\/a><\/span><\/div>
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Ji\u0159\u00ed Ra\u0161ka
\nObchodn\u00ed \u0159editel<\/p><\/h3><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div>

Ji\u0159\u00ed Ra\u0161ka vystudoval obor Fyzik\u00e1ln\u00ed chemie na Univerzit\u011b Pardubice, kde pozd\u011bji absolvoval i doktorsk\u00e9 studium ve stejn\u00e9m oboru. Od roku 2004 p\u016fsobil na pozici vedouc\u00edho QC ve farmaceutick\u00e9 v\u00fdrobn\u00ed spole\u010dnosti Contipro Group,<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
v letech 2006-2008 pak na pozici vedouc\u00edho QC a projektov\u00e9ho mana\u017eera v servisn\u00ed organizaci Lunaria. Mezi lety 2008-2013 zast\u00e1val pozici \u0159editele divize v\u00fdroby a obchodu ve spole\u010dnosti IREL. Od roku 2013 do roku 2018 pracoval jako obchodn\u00ed \u0159editel \u010desk\u00e9 spole\u010dnosti FARMAK, v\u00fdrobce substanc\u00ed a intermedi\u00e1t\u016f pro farmaceutick\u00fd pr\u016fmysl. Ve spole\u010dnosti QUINTA-ANALYTICA pracuje od roku 2018 a m\u00e1 zodpov\u011bdnost za obchodn\u00ed a marketingov\u00e9 aktivity spole\u010dnosti.<\/div><\/div><\/div><\/div><\/div>
<\/a><\/span><\/div>
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Martin Mi\u010dka
\nFinan\u010dn\u00ed \u0159editel<\/p><\/h3><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div>

Martin Mi\u010dka absolvoval Vysokou \u0161kolu ekonomickou v Praze, Fakultu mezin\u00e1rodn\u00edch vztah\u016f a vedlej\u0161\u00ed specializaci na Fakult\u011b podnikohospod\u00e1\u0159sk\u00e9. Od roku 2003 zast\u00e1val r\u016fzn\u00e9 vedouc\u00ed finan\u010dn\u00ed pozice v Zentiv\u011b \u010cesk\u00e1 republika a \u00fa\u010dastnil se prvn\u00edho IPO ve v\u00fdchodn\u00ed Evrop\u011b.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
V roce 2009 nastoupil do biofarmaceutick\u00e9 spole\u010dnosti Actelion jako finan\u010dn\u00ed mana\u017eer pro \u010ceskou a Slovenskou republiku a od roku 2015 zde p\u016fsobil jako gener\u00e1ln\u00ed \u0159editel. V z\u00e1\u0159\u00ed 2022 se stal nov\u00fdm CFO spole\u010dnosti QUINTA-ANALYTICA.<\/div><\/div><\/div><\/div><\/div>
<\/a><\/span><\/div>
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Jaroslava Filippi
\nVedouc\u00ed HR odd\u011blen\u00ed<\/p><\/h3><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div>

Jaroslava Filippi studovala \u010cVUT v Praze, fakultu strojn\u00ed se zam\u011b\u0159en\u00edm na ekonomiku a \u0159\u00edzen\u00ed podniku. Od roku 2008 pracovala na mana\u017eersk\u00fdch pozic\u00edch v oblasti ekonomiky pr\u00e1ce a HR.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
\n

Sv\u00e9 pracovn\u00ed zku\u0161enosti z\u00edskala z prost\u0159ed\u00ed Komer\u010dn\u00ed banky, leteck\u00e9ho pr\u016fmyslu spole\u010dnosti VZL\u00da, organiza\u010dn\u00ed slo\u017eky st\u00e1tu \u010cPI a stavebn\u00ed spole\u010dnosti Carl Stahl. V posledn\u00edch \u0161esti letech se v\u011bnovala p\u0159edev\u0161\u00edm p\u00e9\u010di o zam\u011bstnance, jejich profesn\u00edmu rozvoji a komunikaci na pracovi\u0161ti. V\u00a0Quinta \u2013 Analytica pracuje od poloviny roku 2023, p\u0159i\u010dem\u017e v\u00a0lednu 2024 postoupila na pozici vedouc\u00edho HR odd\u011blen\u00ed.<\/p>\n<\/div><\/div><\/div><\/div><\/div>

<\/a><\/span><\/div>
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Richard Viskup
\nVedouc\u00ed QA odd\u011blen\u00ed<\/p><\/h3><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div>

Richard Viskup vystudoval obor klinick\u00e1 farmacie na Farmaceutick\u00e9 fakult\u011b Univerzity Komensk\u00e9ho v Bratislav\u011b. Od roku 1997 zast\u00e1val r\u016fzn\u00e9 pozice v oblasti v\u00fdzkumu a v\u00fdvoje a projektov\u00e9ho \u0159\u00edzen\u00ed ve spole\u010dnostech jako PLIVA-Lachema, VUAB Pharma nebo Glenmark Pharmaceuticals.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
V roce 2012 se stal mana\u017eerem produktov\u00e9ho portfolia ve spole\u010dnosti Apotex a v roce 2018 p\u016fsobil jako Business Development Director ve spole\u010dnosti Farmak. V roce 2022 nastoupil do spole\u010dnosti QUINTA-ANALYTICA jako vedouc\u00ed odd\u011blen\u00ed kvality.<\/div><\/div><\/div><\/div><\/div>
<\/a><\/span><\/div>
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Kate\u0159ina B\u00edlkov\u00e1
\nVedouc\u00ed klinik<\/p><\/h3><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div>

Kate\u0159ina B\u00edlkov\u00e1 m\u00e1 doktor\u00e1t z biochemie z Univerzity chemick\u00e9 technologie v Praze (UCT) a je tak\u00e9 \u010dlenkou p\u0159edstavenstva ACRO-CZ. Do na\u0161\u00ed organizace p\u0159in\u00e1\u0161\u00ed t\u00e9m\u011b\u0159 20 let zku\u0161enost\u00ed v klinick\u00e9m v\u00fdzkumu, provozu, monitorov\u00e1n\u00ed a \u0159\u00edzen\u00ed.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
\n

Od roku 2006 do roku 2022 pracovala v Premier Research na r\u016fzn\u00fdch klinick\u00fdch pozic\u00edch a\u017e do roku 2023, kdy se stala vedouc\u00ed klinick\u00e9ho odd\u011blen\u00ed ve spole\u010dnosti QUINTA-ANALYTICA.<\/p>\n<\/div><\/div><\/div><\/div><\/div>

<\/a><\/span><\/div>
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Robert Khaddour
\nVedouc\u00ed IT\/TD<\/p><\/h3><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div>

Vystudoval \u010cVUT v Praze Fakultu elektro-technickou. Od roku 2001 pracoval v \u00dastavu fyziky plazmatu jako spr\u00e1vce po\u010d\u00edta\u010dov\u00e9 s\u00edt\u011b.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
Od roku 2002 pracuje ve spole\u010dnosti QUINTA-ANALYTICA nejprve na pozici IT mana\u017eera pozd\u011bji jako vedouc\u00ed Technick\u00e9ho odd\u011blen\u00ed.<\/div><\/div><\/div><\/div><\/div>
<\/a><\/span><\/div>
<\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/span>

V\u011bdeck\u00e1 rada<\/h2><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Ji\u0159\u00ed
\nMichal<\/h3><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div>

Po absolvov\u00e1n\u00ed V\u0160CHT v Praze pracoval 36 let ve farmaceutick\u00e9m pr\u016fmyslu. Od roku 1990 p\u016fsobil ve funkci CEO nejv\u011bt\u0161\u00ed farmaceutick\u00e9 firmy a stal se zakladatelem nov\u00e9ho farmaceutick\u00e9ho pr\u016fmyslu v \u010cesk\u00e9 republice.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
S firmou L\u00e9\u010diva (od roku 2003 Zentiva) pro\u0161el privatizac\u00ed (MBO), provedl t\u0159i v\u00fdznamn\u00e9 akvizice farmaceutick\u00fdch firem (Slovensko, Rumunsko, Turecko), provedl prvn\u00ed IPO na Pra\u017esk\u00e9 burze od r. 1990 a po p\u0159evzet\u00ed firmy nadn\u00e1rodn\u00ed korporac\u00ed (Sanofi) opustil exekutivn\u00ed pozice. V roce 2010 p\u0159evzal z rukou prezidenta republiky V\u00e1clava Klause Medaili Za z\u00e1sluhy o st\u00e1t v oblasti hospod\u00e1\u0159sk\u00e9. Po r. 2010 pracuje ve spr\u00e1vn\u00edch rad\u00e1ch V\u0160CHT a UK Praha, je \u010dlenem poradn\u00edho org\u00e1nu p\u0159i \u00daOCHB Praha, v letech 2013-2015 byl \u010dlenem BOD nadn\u00e1rodn\u00ed firmy Actavis.<\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

V\u00e1clav
\nRejholec<\/h3><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div>

Po absolvov\u00e1n\u00ed Fakulta technick\u00e9 a jadern\u00e9 fyziky \u010cVUT a postgradu\u00e1ln\u00edm vzd\u011bl\u00e1n\u00ed na \u00dastavu fyzik\u00e1ln\u00ed chemie \u010ceskoslovensk\u00e9 akademie v\u011bd pracoval na r\u016fzn\u00fdch pozic\u00edch na V\u00fdzkumn\u00e9m \u00fastavu pro farmacii a biochemii v Praze.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
Pozd\u011bji p\u016fsobil ve spole\u010dnosti Zentiva na pozici \u0159editele a vicepresidenta pro v\u00fdzkum a v\u00fdvoj. V letech 2011-2015 byl p\u0159edsedou Kontroln\u00ed rady Grantov\u00e9 agentury \u010cR. V sou\u010dasnosti poskytuje odborn\u00e9 konsultace v oblasti farmaceutick\u00e9ho pr\u016fmyslu. Je autorem a spoluautorem vice ne\u017e 50 publikac\u00ed tematicky zam\u011b\u0159en\u00fdch na kvantovou chemii, vztahy mezi strukturou a aktivitou a farmakokinetiku.<\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

V\u00edt
\nPerl\u00edk<\/h3><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div>

V sou\u010dasn\u00e9 dob\u011b p\u016fsob\u00ed jako nez\u00e1visl\u00fd konzultant v oblastech regula\u010dn\u00ed v\u011bdy a klinick\u00e9ho v\u00fdvoje. M\u00e1 rozs\u00e1hl\u00e9 znalosti o strategi\u00edch\/n\u00e1vrz\u00edch studi\u00ed\/vyt\u011b\u017eov\u00e1n\u00ed dat v oblasti klinick\u00e9ho v\u00fdvoje, v\u011bdeck\u00e9 podpory\/vyhodnocov\u00e1n\u00ed a interpretace dat. Tyto znalosti z\u00edskal v nadn\u00e1rodn\u00edch farmaceutick\u00fdch spole\u010dnostech, nap\u0159. Pharminvent, Sanofi, Zentiva Inhalationprodukte a Zentiva.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
M\u00e1 za sebou v\u00edce ne\u017e 19 let zku\u0161enost\u00ed v oblastech klinick\u00e9 farmakologie a studi\u00edch f\u00e1ze I, f\u00e1ze II i f\u00e1ze III, p\u0159edev\u0161\u00edm v oblasti v\u00fdvoje inhala\u010dn\u00edch l\u00e9\u010div, generick\u00e9ho v\u00fdvoje a \u0159\u00edzen\u00ed bolesti a obezity. Vzd\u011bl\u00e1n\u00ed z\u00edskal na 3. l\u00e9ka\u0159sk\u00e9 fakult\u011b Univerzity Karlovy a vedle pr\u00e1ce na odd\u011blen\u00ed infek\u010dn\u00edch chorob v nemocnici Bulovka p\u016fsobil tak\u00e9 3 roky ve funkci postdoktorandsk\u00e9ho v\u011bdeck\u00e9ho pracovn\u00edka ve Zdravov\u011bdn\u00e9m centru University of Tennessee v USA. Jako profesion\u00e1l poskytoval n\u00e1vrhy, strategick\u00fd v\u00fdvoj a vyt\u011b\u017eov\u00e1n\u00ed dat bioekvivalen\u010dn\u00edch, farmakodynamick\u00fdch a klinick\u00fdch studi\u00ed, kter\u00e9 vedly k \u010detn\u00fdm \u00fasp\u011b\u0161n\u00fdm autorizac\u00edm na trhu. Je tak\u00e9 zakladatelem a organiz\u00e1torem BioBridges, konferen\u010dn\u00ed platformy pro profesion\u00e1ly z oblasti farmaceutick\u00e9ho v\u00fdvoje, klinick\u00e9ho\/bioekvivalen\u010dn\u00edho v\u00fdvoje a regula\u010dn\u00edch org\u00e1n\u016f.<\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Miroslav
\nRyska<\/h3><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div>

Absolvent Chemick\u00e9 fakulty na Moskevsk\u00e9 st\u00e1tn\u00ed univerzit\u011b. Pracoval na \u00dastavu makromolekul\u00e1rn\u00ed chemie \u010cSAV a V\u00fdzkumn\u00e9m \u00fastavu pro farmacii a biochemii v Praze. Zakladatel laborato\u0159e hmotnostn\u00ed spektroskopie u prof. Wichterleho a pozd\u011bji tak\u00e9 na V\u00fdzkumn\u00e9m \u00fastavu pro farmacii a biochemii v Praze.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
V roce 1997 zalo\u017eil spole\u010dnost QUINTA-ANALYTICA s.r.o., ve kter\u00e9 byl a\u017e do roku 2006 jej\u00edm presidentem. Byl a je \u010dlenem n\u011bkolika v\u011bdeck\u00fdch spole\u010dnost\u00ed, jako Spektroskopick\u00e1 spole\u010dnost J.M. Marci (\u010destn\u00e9 \u010dlenstv\u00ed), \u010cesk\u00e1 spole\u010dnost pro hmotnostn\u00ed spektrometrii, N\u011bmeck\u00e1 skupina pro hmotnostn\u00ed spektrometrii a dal\u0161\u00edch. Je autorem nebo spoluautorem v\u00edce ne\u017e 100 publikac\u00ed zam\u011b\u0159en\u00fdch na hmotnostn\u00ed spektroskopii, stopovou anal\u00fdzu, anal\u00fdzu l\u00e9k\u016f a metabolit\u016f aj. B\u011bhem sv\u00e9 kari\u00e9ry vedl jako Study Director v\u00edce ne\u017e 350 BE\/BA studi\u00ed. V sou\u010dasnosti je konzultantem spole\u010dnosti QUINTA-ANALYTICA, a tak\u00e9 \u010dlenem Dozor\u010d\u00ed Rady spole\u010dnosti.<\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/span>

Kay
\nO’Shea<\/h3><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div>

Kay O\u2019Shea vystudovala bakal\u00e1\u0159sk\u00fd program v oboru Pr\u016fmyslov\u00e1 chemie na Univerzit\u011b v Limericku v Irsku v roce 1987. Ve farmaceutick\u00e9m pr\u016fmyslu pracuje ji\u017e 32 let v r\u016fzn\u00fdch rol\u00edch v oblasti regula\u010dn\u00edch z\u00e1le\u017eitost\u00ed, v\u00fdzkumu a v\u00fdvoje, projektov\u00e9ho managementu a klinick\u00e9ho v\u00fdzkumu. Spolu se sv\u00fdm tehdej\u0161\u00edm obchodn\u00edm partnerem 9 let provozovala vlastn\u00ed poradenskou spole\u010dnost Ivowen zam\u011b\u0159enou na regula\u010dn\u00ed z\u00e1le\u017eitosti.<\/p>\n<\/div>

<\/i><\/i><\/span>v\u00edce<\/span><\/a><\/h4><\/div>
V roce 2010 nastoupila do firmy EirGen Pharma, kde a\u017e do jej\u00edho odchodu v \u010dervnu 2019 zast\u00e1vala funkci vedouc\u00ed v\u011bdeck\u00fdch z\u00e1le\u017eitost\u00ed v r\u00e1mci Senior Leadership Teamu. V r\u00e1mci sv\u00e9 pozice ve spole\u010dnosti EirGen m\u011bla na starosti regula\u010dn\u00ed a klinick\u00e9 z\u00e1le\u017eitosti a z\u0159\u00edzen\u00ed Odd\u011blen\u00ed pro \u0159\u00edzen\u00ed projekt\u016f (PMO), kter\u00e9 m\u011blo spole\u010dnosti EirGen umo\u017enit dod\u00e1vku projekt\u016f na v\u00edce platform\u00e1ch v\u010detn\u011b Oral Solid Dose (peror\u00e1ln\u00ed pevn\u00e1 forma), Sterile Fill Finish (aseptick\u00e1 linka), inovativn\u00ed veterin\u00e1rn\u00ed l\u00e9\u010diva pro zv\u00ed\u0159ata chovan\u00e1 v mal\u00e9m prostoru a inovativn\u00ed modifikovan\u00e9 v\u00fdstupn\u00ed OSD formulace pro mate\u0159skou spole\u010dnost EirGenu, spole\u010dnost OPKO. Ve sv\u00e9 32let\u00e9 praxi pracovala tak\u00e9 jako chemik analytick\u00e9ho v\u00fdvoje v laborato\u0159i ve spole\u010dnosti Clonmel Healthcare (platformy zahrnovaly OSD a or\u00e1ln\u00ed kapaliny), vedla laborato\u0159e pro v\u00fdzkum a v\u00fdvoj v oblasti inhalace ve spole\u010dnosti IVAX, a vedla odd\u011blen\u00ed regula\u010dn\u00edch z\u00e1le\u017eitost\u00ed v\u010detn\u011b \u0159\u00edzen\u00ed bioekvivalen\u010dn\u00edch stud\u00ed a laborato\u0159 pro v\u00fdzkum a v\u00fdvoj ve spole\u010dnosti Niche Generics.<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/span>

Kompletn\u00ed \u0159e\u0161en\u00ed<\/h2><\/span>
<\/div><\/div><\/div><\/div><\/div>
<\/span><\/a><\/span>
<\/div><\/div><\/span>

FARMACEUTICK\u00c9 ANAL\u00ddZY<\/h3><\/span>
<\/div><\/div><\/div>
<\/div><\/div><\/span>

V\u00fdzkum, v\u00fdvoj a validace metod, kontrola kvality, stabilitn\u00ed studie, propou\u0161t\u011bn\u00ed \u0161ar\u017e\u00ed a dal\u0161\u00ed.<\/p><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/a><\/span>
<\/div><\/div><\/span>

KLINICK\u00c9
\nTESTOV\u00c1N\u00cd<\/p><\/h3><\/span>

<\/div><\/div><\/div>
<\/div><\/div><\/span>

Na\u0161e klinick\u00e9 odd\u011blen\u00ed funguje ji\u017e od roku 2007 a eviduje v\u00edce ne\u017e 300 BA\/BE\/PK dokon\u010den\u00fdch studii.<\/p><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/a><\/span>
<\/div><\/div><\/span>

BIOANALYTICK\u00c9
\nTESTOV\u00c1N\u00cd<\/p><\/h3><\/span>

<\/div><\/div><\/div>
<\/div><\/div><\/span>

Analytick\u00e9 slu\u017eby pro studie od preklinick\u00e9ho testov\u00e1n\u00ed po f\u00e1zi III., v\u010detn\u011b statistick\u00e9ho vyhodnocen\u00ed.<\/p><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/a><\/span>
<\/div><\/div><\/span>

ANALYTICK\u00dd V\u00ddZKUM A V\u00ddVOJ<\/h3><\/span>
<\/div><\/div><\/div>
<\/div><\/div><\/span>

Development of analytical methods, impurities research, degradation studies, trace analyses and more.<\/p><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/a><\/span>
<\/div><\/div><\/span>

BIOFARMACEUTICK\u00c9 ANAL\u00ddZY<\/h3><\/span>
<\/div><\/div><\/div>
<\/div><\/div><\/span>

Determination of substances in biological matrices including the statistical evaluation of pharmaceutical parameters and bioequivalence.<\/p><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/a><\/span>
<\/div><\/div><\/span>

A MNOHEM V\u00cdCE<\/h3><\/span>
<\/div><\/div><\/div>
<\/div><\/div><\/span>

Nen\u00ed to vy\u010derp\u00e1vaj\u00edc\u00ed seznam na\u0161ich aktivit, tak\u017ee pokud nevid\u00edte, co pot\u0159ebujete, nev\u00e1hejte n\u00e1s kontaktovat.<\/p><\/span>

<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/span>

Pln\u011b certifikov\u00e1no<\/h2><\/span>
<\/div><\/div><\/div>

As holders of GMP, GLP and GCP certifications for human medicinal products, and GMP certification for veterinary medicinal products, Quinta is regularly, and successfully, audited by the State Institute for Drug Control (S\u00daKL) and US FDA.<\/p>\n

All of our licenses and certifications are available for download below.<\/p>\n<\/div>

GMP Certificates of Compliance<\/h4>\n

Manufacturer \u2013 HIMP (Quality Control) \u2013 Prague Site<\/a>
\nManufacturer \u2013 HMP (Quality Control) \u2013 Prague Site<\/a>
\nControl Laboratory (Veterinary) \u2013 Prague site<\/a><\/p>\n

Manufacturer \u2013 HIMP (Quality Control) \u2013 Brno Site<\/a>
\nManufacturer \u2013 HMP (Quality Control) \u2013 Brno Site<\/a>
\nControl Laboratory (Veterinary) \u2013 Brno site<\/a><\/p>\n

GLP Certificate<\/strong><\/h4>\n

Certificate of Good Laboratory Practice<\/a><\/p>\n

GCP Certificate<\/h4>\n

Certificate of Good Clinical Practice \u2013 Prague site<\/a>
\nCertificate of Good Clinical Practice \u2013 Ostrava clinic<\/a><\/p>\n

FDA Inspections<\/h4>\n

Our company is proud to have successfully undergone more than 12 inspections by the FDA over the last years. Our dedicated Quality Assurance team can produce relevant documentation upon request. For additional information visit the U.S. FDA data dashboard<\/a>.<\/p>\n<\/div>

<\/span><\/div><\/div><\/div>

If you\u2019re unable to download these certificates, please contact us\u00a0quinta@quinta.cz<\/a>\u00a0and we\u2019ll be happy to email them to you.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div><\/div><\/div><\/div><\/div><\/div>\n
<\/span><\/a><\/span>
<\/div><\/div><\/span>

More about Quinta<\/h4><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/a><\/span>
<\/div><\/div><\/span>

Kompletn\u00ed \u0159e\u0161en\u00ed<\/h4><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/a><\/span>
<\/div><\/div><\/span>

Novinky<\/h4><\/span>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n
<\/div><\/div><\/span>

M\u00e1te dotazy?<\/h2><\/span>
<\/div><\/div><\/div>

Kontaktujte n\u00e1s p\u0159\u00edmo nebo pomoc\u00ed n\u00ed\u017ee uveden\u00e9ho formul\u00e1\u0159e.<\/p>\n<\/div>

quinta@quinta.cz<\/p>\n<\/div><\/div><\/div>

+420 242 454 311<\/p>\n<\/div><\/div><\/div><\/div>\n

\n

<\/p>

    <\/ul><\/div>\n
    \n
    \n<\/fieldset>\n
    \n
    <\/span><\/div>\n
    <\/span><\/div>\n
    <\/span><\/div>\n